| Drug Class | Sponsor and/or Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| ATP Synthase Inhibitor | Global Alliance for TB Drug Development | TBAJ-876 | | Phase 1 | Completed | |
| Antibody, Monoclonal | National University, Singapore | Pascolizumab | Anti-IL-4 Antibody | Phase 2 | Unknown | |
| Cell Wall Synthesis Inhibitor | Innovative Medicines for Tuberculosis; Nearmedic Plus LLC | Macozinone | MCZ; PBTZ-169 | Phase 1 | Completed |
573761
|
| Cell Wall Synthesis Inhibitor | University Medical Center Groningen | Invanz™ | Ertapenem | Phase 2 | Completed |
604819
|
| Cell Wall Synthesis Inhibitor | National University, Singapore; Asubio Pharma | Farom™ | Faropenem | Phase 2 | Completed |
545326
|
| Cell Wall Synthesis Inhibitor | Johns Hopkins University | Merrem™ | Meropenem; SM-7338 | Phase 2 | Completed |
007788
|
| Cell Wall Synthesis Inhibitor | Otsuka Pharm | OPC-167832 | 3,4-dihydrocarbostyril derivative | Phase 1/2 | Completed | |
| Cell Wall Synthesis Inhibitor | European and Developing Countries Clinical Trials Partnership (EDCTP); Michael Hoelscher, Ludwig-Maximilians, University of Munich | BTZ043 | Benzothiazinone derivative | Phase 2 | Not Yet Recruiting |
538411
|
| Cell Wall Synthesis Inhibitor | European and Developing Countries Clinical Trials Partnership (EDCTP); Sequella | SQ-109 | A novel 1,2-ethylene diamine | Phase 2 | Completed |
207396
|
| Cell Wall Synthesis Inhibitor | Global Alliance for TB Drug Development | TBA-7371 | An azaindole | Phase 2 | Completed |
555726
|
| Cholesterol Catabolism Inhibitor | GlaxoSmithKline | GSK2556286 | GSK-286 | Phase 1 | Recruiting | |
| Combination | University Medical Center Groningen, Netherlands | Isoniazid & Co-Trimoxazole (Trimethoprim & Sulfamethoxazole) | | Phase 3 | Completed |
000307
|
| Combination | The HIV Netherlands Australia Thailand Research Collaboration | Indinavir & Ritonavir & Rifampicin | | Phase 1/2 | Completed | |
| Combination | Global Alliance for TB Drug Development | Midazolam & PA-824 | | Phase 1 | Completed | |
| Combination | Pfizer | Lersivirine (UK-453,061) & Rifabutin | | Phase 1 | Completed | |
| Combination | National University Hospital, Singapore | Celecoxib & Rifampicin & Pyrazinamide | | Phase 1 | Completed | |
| Combination | National Taiwan University Hospital | Rifapentine & Isoniazid | Combination for latent tuberculosis treatment | Phase 3 | Recruiting |
070133
|
| Combination | Walter K. Kraft, Thomas Jefferson University; Merck Sharp & Dohme Corp. | Doravirine & Rifapentine & Isoniazid | Combination for latent tuberculosis treatment | Phase 1 | Completed | |
| Combination | Global Alliance for TB Drug Development | BPaMZ | Bedaquiline & Pretomanid & Moxifloxacin & Pyrazinamide | Phase 2/3 | Completed | |
| Combination | National University Hospital, Singapore | Faropenem & Amoxicillin (Clavulanic Acid) & Cefadroxil & Rifampicin | | Phase 2 | Completed | |
| Combination | National Institute of Allergy and Infectious Diseases (NIAID) | Imatinib & Isoniazid & Rifabutin | | Phase 2 | Completed | |
| Cytochrome bc1 Complex Inhibitor | Qurient Co., Ltd. | Telacebec | Q203 | Phase 2 | Completed |
594207
|
| DNA Methyltransferase Inhibitor | Baylor College of Medicine; Celgene Corporation | Vidaza™ | Azacitidine; Azacytidine | Phase 1/2 | Withdrawn |
000615
|
| DNA Replication Inhibitor/TB Cell Division Inhibitor | Global Alliance for TB Drug Development; Bayer; Schering-Plough | Avelox™ | Moxifloxacin; MXFX; BAY 12-8039; Actira | Phase 3 | Completed |
070017
|
| DNA Replication Inhibitor/TB Cell Division Inhibitor | IUATLD, Inc ; Daiichi Pharm; Sanofi-Aventis; Ortho-McNeil | Levaquin™; Tavanic™ | S-(-)-Ofloxacin; DR-3355; RWJ-25213; Cravit; L-Ofloxacin; Levofloxacin; LVX | Phase 3 | Active, Not Recruiting |
002307
|
| DNA Replication Inhibitor/TB Cell Division Inhibitor | National Institute of Allergy and Infectious Diseases (NIAID); Bayer | Flagyl™ | Metronidazole; Bayer 5360; Clont; Danizol; Gineflavir; Metric 21; Trichazol; Trichopal; Trivazol; Vagilen | Phase 2 | Completed |
007953
|
| DNA Replication Inhibitor/TB Cell Division Inhibitor | National Institute of Allergy and Infectious Diseases (NIAID); Parke-Davis; Kyorin Pharm; Pfizer | Tequin™ | Gatifloxacin; GTFX; BMS-206584; AM-1155; CG 5501; PD-135432; GAT | Phase 3 | Unknown |
044913
|
| GyrB ATPase Inhibitor | Spero Therapeutics, LLC | SPR720 | VXc-100, VXc-486; An ethyl urea benzimidazole | Phase 2 | Terminated | |
| Host-directed Therapy | Johns Hopkins University | Pravachol™ | Pravastatin | Phase 2 | Completed |
488445
|
| Leucyl-tRNA Synthetase (LeuRS) Inhibitor | GlaxoSmithKline | GSK3036656 | GSK070 | Phase 2 | Completed |
599488
|
| Mycolic Acid Biosynthesis Inhibitor | Wits Health Consortium (Pty) Ltd; Otsuka Pharm | Deltyba™ | Delamanid; OPC-67683 | Phase 3 | Active, Not Recruiting |
182259
|
| Protein Synthesis Inhibitor | MicuRx Pharmaceuticals | MRX-4 | Prodrug of Contezolid (MRX-1) | Phase 1 | Completed | |
| Protein Synthesis Inhibitor/TB Growth Inhibitor | Global Alliance for TB Drug Development | TBI-223 | Novel oxazolidinone | Phase 1 | Completed |
592820
|
| Protein Synthesis Inhibitor/TB Growth Inhibitor | National University Hospital, Singapore | Vibramycin™ | Doxycycline | Phase 3 | Not Yet Recruitung |
000242
|
| Protein Synthesis Inhibitor/TB Growth Inhibitor | European and Developing Countries Clinical Trials Partnership (EDCTP); Pharmacia & Upjohn, Inc.; Pfizer | Sutezolid | PNU-100480; PF-02341272; Oxazolidininone | Phase 2 | Completed |
045415
|
| Protein Synthesis Inhibitor/TB Growth Inhibitor | LegoChem Biosciences, Inc. | Delpazolid | LCB01-0371 | Phase 2 | Completed |
581214
|
| Protein Synthesis Inhibitor/TB Growth Inhibitor | Global Alliance for TB Drug Development; Pharmacia & Upjohn, Inc.; Pfizer | Zyvox™ | Linezolid; LZD; PNU-100766 | Phase 3 | Completed |
070944
|
| Pyruvate-Ferredoxin Oxidoreductase Inhibitor | Weill Medical College of Cornell University | Alinia™ ; Nizonide™ | Nitazoxanide | Phase 2 | Completed |
057131
|
| Unidentified | Scientific Center for Anti-infectious Drugs, Kazakhstan | FS-1 | Molecular iodine complex with bioorganic ligands, magnesium and lithium halogenides | Phase 3 | Completed | |